ENTA - Earnings call transcript Q3 2020 | Enanta Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. And welcome to Enanta Pharmaceuticals' Fiscal Third Quarter Conference Call. [Operator Instructions]. I will now turn the call over to Jennifer Viera, Senior Director, Investor Relations. Please go ahead.

Jennifer Viera

thanks for and afternoon. us operator, you, to joining everyone this Thank our news results afternoon issued on financial with and the available The our was for release recent quarter is website. this

Dr. Jay the Officer; Mellett, team. of Chief our today members On Officer; other senior Luly, Paul and call Financial Enanta's and Chief President Executive is management

Form respect statements, XX-Q other assumptions to filed actual differ statements. to Enanta to to not which and we I'd the will Dr. that we with Jay begin made reports those does you the and plans SEC. and President description candidates our to with CEO. Before call. product this beyond cause over from statements any results now any involve risks forward-looking A our making our formal like control which forward-looking Jay? financial update remind expectations recent turn of our and include obligation remarks, is could during and that to with and undertake these I periodic materially want most all of our may in be developments projections, Luly, our risks certain call

Jay Luly

steatohepatitis and Paul and for in B On quarter. respiratory preclinical everyone. SARS-CoV-X and and pleased liver for our disease, our human non-alcoholic we've call, hepatitis. virology across the Thank Good us today. is joining will focused pipeline, programs I I'm with syncytial financials which hepatitis discuss pipeline, updates Jennifer. you, during the Thank areas X virus, this to expertise, of afternoon, the progress metapneumovirus, the review will clinical virus, across report you made quarter on our

companies, to We're will of take Foletta, formal Mark Committee. of be want and pleased in for and will to serving he viral Mark be welcome treatments Nominating and diseases. Financial Committee Directors. experience, to the previously appointment the Chief to of has Amylin Mark of announced pipeline Governance as healthiness advance our governance serve biopharma get remarks, operating we very will extensive member team, liver as into our our where Audit innovative a a my including various Before Pharmaceuticals. financial, and June in Mark we have for join I as infections Board instrumental whose I moment Chair Officer

a continues our has Additionally, and Enanta. team team of to Despite I ensure to ongoing on backdrop the that want business resiliency take and stay to of to moments able here mature. focused pipeline progresses few at that our the pandemic, the COVID-XX comment the been our

where programs, expertise tested our core our we develop and nuc-suppressed our discover clinical we and patients. being I'll both compounds, move a patients leveraging currently inhibitor multiple to We continuing discovery antiviral end, with begin ongoing human different metapneumovirus this have studies X we are quarter, clinic virology-focused our with to the product To develop to with HBV candidates. HBV and candidates EDP-XXX, I'll lead for work drug preparing that are HBV fourth and SARS-CoV-X. our is are program viremic that into in in start compound

We on be viremic that unmet placebo trial than need Taiwan, which more with and as HBV at not treatment. we of placebo-controlled of double-blind, that areas are and announced enroll ascending In orally pharmacokinetics July, multiple This sites in designed early doses over EDP-XXX receive Ib XXX estimated large randomized subjects, antiviral X currently Ib XX-day million treatment disease The both HBV Kong activity the Phase worldwide. safety, we subjects in therapy of administered are true to it randomized, chronic need. It's a or initiated Hong patients. a tolerability, HBV a HBV is period. a Phase clinical a XX clinical in developing trial EDP-XXX with affects for our to will study committed our is for evaluate X to people planned who to unmet is viremic study HBV

doses orally EDP-XXX and study COVID-XX in Ia/Ib is Phase paused patients. multiple to As XX pharmacokinetics of is refer a subjects, first who any expect X ascending of will to Phase regions, monitor of which Barring inhibitors, to EDP-XXX activity also planned Part pandemic, disruptions, have we with data ascending chronic to the period. second XXXX. which multiple impact as due in in further X X is patients the randomized, of or administered tolerability, nucleoside data quarter was the safety, in HBV treated double-blind, reverse study trial our of XXXX. enroll from COVID-XX of XX-day placebo. antiviral the this March over nuc-suppressed study. study, we receive to X Part to doses evaluate half in we designed these transcriptase resumed our This ongoing we continue COVID-XX the preliminary of Ib to of be We've placebo-controlled plan preliminary randomized The

plan study and from presentation poster at a a healthy the Part EASL's Digital in August XX through to XX. present being of first-in-human at Liver volunteers reminder, data we held International X As Phase Congress I

immune-compromised from therapy. line mortality has now II RSV RSV EDP-XXX syncytial and and A elderly symptom infection non-fusion in in and RSV significant turn potent RSV. study. a a viral human and a and effective reduction inhibitor B respiratory is virus, currently Phase and shown and the of a condition there with in load to respiratory is challenge been top safe data significant no resolution morbidity associated or our infants, is for adults which and EDP-XXX a Let's severe for program

initiating XX Phase of RSVP, as sites study the IIb, fall a designed up days. are evaluate randomized approximately the XX is on this EDP-XXX and effect or to XXX for our of a with The and is our the of the of to either EDP-XXX subjects season of ready progression placebo RSV placebo-controlled currently milligrams XX-day primary EDP-XXX, infection new receive and as double-blind, arrival by point. end sites is study in RSVP ongoing objective for the well X clinical age Southern winter for also RSV American years sites study observation measured of assessment EDP-XXX Europe. of of evaluated Hemisphere symptoms IIb of of course key viral efficacy of adding North number the period, existing enroll to the in a secondary over the study Phase We any RSV keeping be -- as will are reactivation to

EDP-XXX, the are randomized, will study for approved be RSVP regimens and a study EDP-XXX pediatric based nonhospitalized double-blind, impact II on evaluate transplant one additional EDP-XXX an pediatric in on positive quarter days months to infants RSVP one RSV or placebo-controlled to dose-ranging who children we hospitalized of to with XX on early test Hemisphere too what Phase we study. recipients XX acute will Phase time effect study assay. placebo-controlled evaluate in enrollment is of Phase transplant of have upcoming adult respiratory infection with to trial studies winter, expect study in tract. adult Northern data RSV the this this in XXXX. II X hematopoietic diagnostic cell of double-blind, initiate to of in transplant COVID-XX The EDP-XXX the it's know IIb the have would While assuming randomized, upper by adult in Meanwhile, a lines, with EDP-XXX aged full patients The patients, concurrent the the end and track to year of third

virology Turning to franchise. on the focused rest our SARS-CoV-X. a remain developing of We candidate for

inhibitors the to strength utilizing targets, often to in understand virus development and polymerase optimization and are We drug referred compound example, These our to exploit protease direct-acting intracellular as for DAAs. and inhibitors. are identify vulnerabilities core antivirals using,

throughout stopping after Chemistry inhibitors already biology we symptoms patients we As than these virus of and RSV, more believe effective year. are the should efforts with hope ongoing, to the remainder be infection. the important DAAs make of actively show and entry progress in

to COPD Moving is young emerging causes drug Earlier to hMPV pathogen program. patients as this hMPV. in our year, as introduced discovery second with or lower or asthma. Similar and human children also RSV, as a and respiratory a those elderly we for in tract upper infections also immunocompromised known the metapneumovirus, program that well on

are hMPV indication. in identify nonviral gears on and our NASH. this liver candidate Shifting work our first currently disease, where clinical perform nanomolar for working We leads current continue our optimization to to to focus of inhibitor aggressively we

without of randomized, IIb The primary end double-blind, subjects of in of Phase studies improvement be and/or placebo-controlled NASH study worsening a will resolution in recruitment in conducting highlighted July. clinical EASL this from data FXR is We EDP-XXX, an oral our be ARGON-X of we agonist. approximately with month, of NASH on ARGON-X are fibrosis. XXX at worsening initiated point NASH. Based ARGON-X in biopsy-proven which fibrosis will first later presentation without ARGON-X, XX-week

strong other We profile selected tolerability. X.X which for XX-week XXXX include which and quickly X information target a in we combinations engagement ARGON-X are interim and assess generate to mid-year in a mechanisms more balanced and to efficacy dose milligrams, for and of provide that analysis, EDP-XXX using we terms targeting will doses are milligrams balance of to NASH. potential with

and that FXR high track EDP-XXX, additionally a XXXX. study in our for be in compelling excited second expect tissue-targeting and are to of We We're NASH. of compared demonstrate later other FXR characteristics I EDP-XXX agonists developing Phase initiate about data data EDP-XXX to development. follow-on quarter agonist this the given pleased to preclinical We're its potency on quarter candidate

Specifically, that tolerability like on for tissues in takeaways. X our EASL with I'd We skin. the versus agonist key important later patients effective forward forward, remarks trial allow We potent, EDP-XXX believe at a the targeted efficacy, viremic and tissue-targeted profile. in of an first namely moving data selective look my plan profile lower to plasma improved month. FXR and by conclude few preclinical half a intestine, XXXX. and preliminary HBV anticipated to of highly doses emphasizing present this We EDP-XXX to for is and posters to liver highly may

second our forward who the Ib the We from Phase are also patients look preliminary in nuc-suppressed by year. results of trial to quarter HBV

where trial ready Southern North in the in studies that winter I season. other adding pediatric turn additional America is ARGON-X continuing EDP-XXX patients our pleased RSV adult also we finally, of sites over financials stop advancing And are in and initiate initiate RSV transplant to quarter. while to are both return this discuss the fall able of the our during in X here next are and about NASH, in the the to the Europe sites to and to Hemisphere, patients Paul? We quarter. for coming trial quarter. begin RSVP excited eager and we were We're to call our on candidates I'll track EDP-XXX the to study and we're Phase Paul

Paul Mellett

results reporting for I'd XX Jay. third ended fiscal that you, XXXX. to schedule. everyone fiscal we like quarter Thank our September XX, remind a on year are June reports Today, Enanta

reported significantly lowest was for royalties total This over quarter decline of below separately amount the billion royalty quarter, worldwide of were entirely to increase volumes sales contractual basis on the rate a X% product, on a rebates royalty our which adjustments This calculated that quarter AbbVie The our just for by highest million with sales. the on in rising consisted royalty now approximately net which determined after blended I'll XX% HCV each rates. which HCV HCV discounts, total having royalty schedule of affected ending compares revenue XX remind the our are XX% at For royalty of $XX.X for royalties, treatments now remain quarter, calendar through AbbVie's $XXX the lower tiered Royalty The revenue revenue for of pandemic. in that at quarterly a expects sales royalty restarted each of XX% would $XX.X sales XX. year net MAVIRET's the million total December calculated rate the a means $X.X and sales, to certain patient pre-COVID and AbbVie's COVID-XX global of million. levels. sales of was everyone are same ending revenue MAVIRET in of due royalty year of as XXXX AbbVie's period rate. decrease in same is set-offs, March our schedule result in XXXX. royalties revenue calendar are of typically earned for

You our XX-K. tier schedule our Form in royalty can XXXX review

Moving expenses. on to our

XXXX. $X.X for of quarter for XXXX, million income totaled expense net X for XXXX, development in months was quarter XXXX. share ended the of million less period $XX.X the to XX, from compared same in of year-end with $XX.X benefit Net in the loss was a development tax compared XXXX $X.X General $XX the or of to our carryback. period, the fiscal June the is months million for federal a and same $XX.X XXXX. common ended This to X credits $X.XX $X.XX for the million in ended million million tax period XX, federal X% income for Enanta's for benefit $XXX and reflects credits and was of X approximately XXXX. net million loss in Enanta loss effective months research was development expense for rate compared diluted the compared quarter. XX% the to research for For cash tax an marketable expenses $X.X federal operating income compared for common the $X due or XXXX, to federal securities, compensation X same increasing XXXX, administrative recorded June the diluted period XXXX. increase XXXX the period to in tax period million increase million rate The million and effective by $X.X of carryback. a our an tax net balance for tax for loss increase income The same XX, Enanta XX, the and than an quarter research net for corresponding ended months benefit approximately per ended per and operating million. driven $XXX.X an in tax approximately and share loss the June June

filed. up for to turn on Operator? call now royalty as and available when revenue Form foreseeable these are the will lines cash financial to continue future. expect I'd continuing We release press open be the our resources available for and as details well sufficient for XX-Q our our our the to anticipated like be the will quarter back the questions. cash meet to requirements that Further operator in

Operator

[Operator Instructions].

from Your with first question comes Eric JPMorgan. Joseph

Eric Joseph

Just a couple from us.

what like just frame How in regimen terms would First quarter. And should dose on you can sorry, in in established nuc-suppressed data us data be if in compelling be would dosing Ib go-forward with there EDP-XXX. go-forward in of results expected yes, wondering sort second the was Jay, I the virals? establishing terms Phase for we Well, that in of what in of there? a objectives expectations that patients look study. a about thinking the are

Jay Luly

Sure. Thanks, Eric.

So this is Jay.

is going flavor why bit the obviously don't that nuc-suppressed nuc-suppressed have quite therapy. And studies, on question actually so the they're on just right So both study XX-day X yes, and a now. get existing folks X of nuc a The compare I the studies? They're we contrast different. for both answer little as an are you but I

quite levels be mentioned, DNA their going as So suppressed. They're to studies. XX-day are both, I already

PK that's out get safety can the nuc. extremely of you nuc-suppressed what context actually important study tolerability So and and of is the in

substantially sure is that XXX are sort study the well B hep nucs. standard and the today to nucs looking with the As plays you know, -- for of treatment, care of make

aim We'll, the given course, not of information, RNA, much antiviral this, XX-day study. of viremic the main study. In nature there but other data e-antigen also different. the bit the s of get of the from little case antigen, expect a to it's that's study, the So too

a we'll so least be significantly at at as for a PK different again, dose-ranging we'll be be quite patient haven't population well. looking DNA on case. a be also, look in study. there. who elevated we'll the to in alone virologic been safety, drug -- year looking parameters at HBV with Again, that But therapy for, XX-day have tolerability, So who patients again, it's We'll levels, and

so antigen, XX-day e-antigen and able So really a it's period. But forth. time over be to DNA, RNA, get s we'll

to some sense I'd solid is that or range we I study, of be a period of that what say terms time that a would XXX something would In of sort well. like a us in X-log give us over that -- more working see viremic would think decrease give

all using that doses. go-forward be to together we'll pick So information

Operator

from Baird. Skorney next is question with Your Brian

Brian Skorney

of Just on we what I by thoughts a think seen the kind is here. guidance. the you of data, III when although hurdle about get seemingly get of Phase your what's the all think FDA OCA, kind the design how ARGON trial within mean when that regulatory post FXR rejection sort and the we first agonist, we've FDA, and about hitting

U.S. Just interested on thoughts, and your approval future. that in getting your outcome how the be FXR for Jay, the we view a should of about of development thinking in

Jay Luly

Sure.

large, actually the KOLs of letter the surprised I response complete community at Street were to some competitors think and think sort there. and Intercept's see certainly, of I all So the Wall

we studies, Intercept, better we meetings to just see think what III the a to package. Phase think having with to little -- need understand is I regards in more Intercept's need some So the agency. understand, had FDA I just information, mind regarding try I bit with

So as over for what's the what and for happened on transparency may and greater in there get others. future time, I think Intercept going to there, lay we'll what's

of it sort intriguing to certainly broad-ranging say we'll how very least, out, just to a that development, question a the for us. it's it's see So need but plays

Our starting at We're in is even middle a path study pretty or straightforward. this the point. not registration

could process here, there around path be extent ways any the could that or little regulatory of move that to we'll studies. the and impacted goalposts plenty it have bit other a incorporate time to into So that are future

We're we that for really down you for dose, to and target also what up at us, ARGON-X. vis-à-vis look tolerability. doses bumping bringing and dose, goalposts we ARGON looked low top the between the it's about exactly for the as study, engagement know steering ARGON-X, know, So in of we're

that sense guidance us again, have behave future. how along you of also of And nicely And Phase the where will well, molecule stare at and the there. tucking and on mid quarter. I good we'll get we'll for the a parameters can then year, of pretty come we that to selection dose to into in good of is agent engagement didn't in the in plan where of of know interim the we've give fine-tuning XXX, clinic. X design have tolerability analysis the follow-on doses sort but it's class. next FXR parallel this ask a very a along that that's And about then healthies, will So same then first the It's separately, understand the our measure those and at out plays that whether the look and path, terms generated both we target thesis an to

be will course that XXX So quarters, second few the and molecule data in quarter on exciting watch, of over the the to of next year. too, that we next expect

Operator

Your with Securities. from is question next JMP Roy Buchanan

Douglas Buchanan

for sites I had is RSV details wondering And on be Where And in Hemisphere, a give couple planning how I RSVP on the can I the targeting based solely the you're you're transplant one to then pediatrics Europe? a in -- looking? trials handful II Southern those tell the I'm can targets how are many on you have U.S.? and many follow-up. if going for had just -- season Phase RSV. us some And you us patients.

Jay Luly

that's were so the out. interesting said, coming with and we're it's the of locked hemisphere. a just that New Southern being But flu watching the is was Hemisphere, Australia that opening plays in in It's to It's after and bit while, to be interesting Southern early how season Southern for setting. things reasonably they late Hemisphere Zealand opened one flu is -- really is So the up. a numbers up winter just different to down kicking RSVP up. going the a little the of see regards --

had the from before did -- season. distancing of otherwise down right travel sort the lot sort and Northern of -- did to be would coming Hemisphere ban severe what is, question winter the they a the social of all the people blocked lockdown that So a the and their Hemisphere Southern

on kind prevention down some take what Northern were start was in happening So practices the they and Hemisphere, to there go to school of able best the early. of

wait which Or they they have as that. planning, it wait been frame are year few our it sites how doing next simply to and adding back the of slide is to be to be answer open have will and and a for and over we anticipated into several plays winter, Europe. up, somehow cold dozens now, up have and Hemisphere, in we they back see We'll weeks have will see a obviously doing can't this a where season? North and And sort blunted be were what now, sort flu in it months. already of and season America which right out of as up a know we'll So to little little things where set dozens a plan shift bit? why the we RSV the But that normal earlier to and we we bit of come when Northern we'll sites is

mitigation, So XXX think think about I not that over total, we're we're as thinking we have with the appropriate. U.S., anticipating we'll strapping And Asia further -- consider I Europe, or and order. sites even be countries might on Canada also whether all on

done the and I the you the a a days. team of job of poised, including -- -- these wild well The So get on answer to it's a we had we're done respiratory peds. little well everything, positioned think that need, at front. question? the testing have the characterization bit question your viruses I Does equipment on that diagnostic think a But sort ride great has on

Douglas Buchanan

going I the -- The was those are was be great. I perfect. transplant U.S.-based trials. that No, solely that just trials, No, wondering to and was curious if was yes. Yes. pediatric if

Jay Luly

as sites So we'll ultimately, be in Northern other adding But ex starting on the well. be we'll U.S. Hemisphere.

Douglas Buchanan

getting quickly. had with social of effect. tested answer. kind it or And possibly off the dropped for U.S. distancing, of kind kind Hemisphere with following reducing was the in follow-up, RSV last it up a and I the answered the the actually when you was Southern -- COVID bystander not your, year think, was I people then negative of Great. that And had season wondering this Okay. a I But and I if

Jay Luly

and That's actually It It a surprising December into gone tailing sort thing. RSV maybe is strange. then And January, COVID of was the Hemisphere Usually, and the very Northern time frame, in in very word. was the before really of peaking so in through presentation. year peaked had sliding come That the was -- March sort and QX. and this whatever for fell reason, typical quickly last February unexpectedly.

year, I hopefully, anomaly. a so think of just getting period, fast -- be So finishing sites study that's way, what would last get Southern as pretty bit bunch but study of all challenge suggested figuring up year, the an that a February either last we're the done. as big X sites the and just the the We've This we'll difference we the and time, the that's were after of But QX we year, January, a end supplementing know, of European down data between could and still Hemisphere. this we we and running we -- year you have can just and up forth, sort the with had as much by the before. then and that RSVP in

it, to of So watch but we'll we're sites. just lots adding continue

Operator

Your Markets. with Abrahams from RBC next Brian question is Capital

Leonid Timashev

on human I is have This the metapneumovirus. Brian. for Leo one on

the be enter see And this to how some with at hinted virus? patients have us clinic the are opportunity And to to the and guys you is identified. you the work program leads perhaps respiratory you've any for there? what for what program RSV Can ultimate need of to will done remind time you educate going So this lines physicians about the be guess, synergy I much there program? this and

Jay Luly

It's of It big on if some be. immune-compromised aware can and flu disease, -- the of of be pretty the some It of migrate and wondering it would picked of metapneumovirus preying and starts causes. everything It pulmonary disease, RSV have leading different cytokine the -- storms for a old, patient sort populations, in sort same to can the what a up can is season And thanks patient you everybody an human get years, sort threat Human same most of Patients inflammation, upper hits airway patient and populations the as rivaling a should part. for much and lower a same so RSV presentation was topic. a on. airway you I hang the was young actually little first -- patient of think a represents as cause does. certainly is XX the meetings, the populations, the known of because you of so some metapneumo the -- to And that RSV be about it's less out And the metapneumo reason number respiratory infection question. characterized if sort ago. at human bit that lot So I years in of there. but second forth. it sort journey. The see

of people medical the community, treat quite this are who So patients, aware virus.

I whole going in out on these and -- that COVID now, top sort different viruses new I people sort RSV done EDP-XXX of along, sort a it's molecules, there's approach add going approach rule so fact you coming that lot of sort came of relative the with that, relatively had think quickly until are respiratory to small taking think new to be just of can things of what viruses. to it's human more a there hasn't People and the than been respiratory and human a And get attention that flu. into lately

now COVID. testing, rule you can You by -- out can

think I increased being of present be, diagnosed then virus. that tested, of getting with And come people care human the I awareness seeking and itself and to they tested, then? when with and medical when thinking think have symptoms, of sort approaches they're you in well, it's portfolio we're of have getting So going to they what do getting a respiratory there lends

thinking when of COVID weren't were perfect was we adjacency. some metapneumo it human time sort we of we back. So a started obviously on was of What thinking

working an sense you're it although another, many, people thinking have a you you're that's RSV, you human one, approach, really an get going perspective, vaccine extraordinary commercial to antidrug. get you If from of on a human sort amount a And -- If in people the obviously. because, vaccines -- want Many get other probably it only they're trying unsuccessfully. to on that they're building about if if be working on if is take are it's Moderna, out company RSV viruses, I metapneumovirus it's And to for again, if business makes another about think it anti-drug. years many tried of diagnosed. respiratory way think

do what And where no no a where treatment a really today. we for class today and therapy drug hope succeeded is treatments have exist new so with forward to vaccines new come

human metapneumo sense. lot So of makes a

where drug Now we? nanomolar it in got that molecules lot. a program. We January JPMorgan. we We've discovery like announced It's are at a

the what Enanta strong that very need So really in apple and to characteristics stage. with clinical the I other successful polishing the is does all which have times would of before, doing has well pretty say taking we're a is you and then interesting done And virology, lead lots trick a optimizing potent, candidate.

sense. I our boxes again, But all And have terrific that interface long. So a got a it we we're now. something But it's think of of makes, before perfect to we'll at hopefully, again, doing. amount too to the program. check that complement other It's

Operator

Instructions]. [Operator

is Olson Jay Oppenheimer. Your from with next question

Jay Olson

to close itself I'm on been or or antibodies your could has DAA. the doing I'm on therapeutic discovery of any informed candidate. that's on if you any there's for virus and recent published comment then maybe And the curious research you the about vaccines that on nominating SARS-CoV-X, are efforts if work how a work wondering you're

Jay Luly

the Thanks, Sure. question. Jay, for

a folks to antibodies know thread you've always other vaccine that that's we burn and different we're at are thinking whether some programs, out it's total but there. as respiratory spike all. had hasn't something on there. approaches interesting -- with now, in something But world is a and What successful vaccine, problem, as compliance, as infections, people many attack that the there assuming this that vaccines compliance humanly likely there's all hoped. can been or it's as prophylax it's about some So with doing be hand, effective -- once biologics. are vaccine, our and very And I'd possible. let's are doing hope of trying or our following really -- one the there's -- say -- to many that are say if lot vaccine, approach SARS-CoV-X vaccines, viral to strategy targets consistent, treat is mercifully, right is sorts our doesn't going I'd or seem from people informed what doesn't proteins as it's assume other bit folks not that the generate people partially on that not people, no I the And of or out.

still with into So after years and put you yourself and could going from vaccines now, if that box a there them important well a a few for very be, lot of in targeted think even around, therapeutics need way.

the people are metapneumo. we treating where at we're ever imagine in people that we put RSV, respiratory shown of where signal to XX to hopefully, down load we one time viral they're human exciting things person's antiviral, to RT-PCR altered be That's able study hours, fairly they our that clinic, get the challenge we've fairly within change the what if with COVID viruses showed. rapidly other or present with other infection. if course or the walk the or get the really they on of some people get from a and -- infection. So in they RSV And drug, -- of that's like is tested a they the have a of determined it's symptomatic, state then RSVP this, viruses And our knock rapidly, trial, that could direct-acting course ought it's can put on an then, which you assay,

that go into to can we So won't do back they people and They can home, be family if be spreading, can a work. super spreaders. people within won't And their hopefully, few go infecting COVID, turning days, with relatives.

if we're Again, early, treat to then go not of you're So the who's that's symptomatic we have where biologic. an with out sort vaccines going do regimen antibody important be follow it opportunity and to an you is down as to attention with incredibly now. vaccine, -- not hard it knock want all is where receiving where oral that aiming. be that's there hit think going that's could as and an into fuse treatment or it and well a not very somebody go this What much going, it's to it's otherwise right

Operator

from is Wolfe with question Research. next Your Akash Tewari

Amy Li

your couple Li for on This on had program. Akash. RSV is just a Amy I

go properly administration as you and adult you XX-hour time how to differences to regards IIb cuts HSCT over also then drug symptom end powering given you pediatric trials, end for in Phase Anything your time of accounted share viral RCP, symptom will in cut-off And likely powering different stratify to you titer, Phase Also, on what for cetera? such evaluating IIb like that baseline design can be First, of type would RSV points very be disease? the assumptions general on studies? have be the an course would your the can points symptom/benefit, baseline factors onset, between on a Phase their you et will the will you in allow and and into of in And helpful. these patients later to your IIa administered in clinical RCP?

Jay Luly

I'm you the on peds sorry. that we anything transplant? said? what or Share share of can design the Is that --

Amy Li

Yes.

Jay Luly

Yes.

related aren't into But that the not start My sure within question now. to study, able in I'll looking sometimes outpatient right biostatisticians very an further according hours within be -- a reach to made dive with at where looked all hours, parameters. study it that study I'm XX the assumptions way empowered XX the we to this trust carefully immediate now. powering powered right at we'll would biostatisticians So those as different be discussions challenge the somebody that have first.

outpatient we're children, looking at We'll of be to looking be be the looking will at safety, or Those terms early to PK. days be things at be, nonhospitalized set study, XX to time the period. period. within as on, a of nonhospitalized the regards XX-hour with hospitalized subjects, be XX-hour With regards and recall, I peds, XX going a going we'll And obviously, to getting be we're months age. hospitalized peds we'll course, the parameters with well. going virologic and looking infants as timing, we've time at I also to of believe again, to In the utmost and

people virologic Looking what complications, cell points looking again, upper at recruiting -- the over respiratory as at and folks, track to transplant well. also RSV PK of we'll respiratory to lower tract. incidence infection evaluate end of we're there have is be parameters we're hematopoietic who of the and acute going in and have We'll the be secondary looking safety while

for I are so that, obviously These be transplant symptoms who think quite in too, have folks immune can of we'll days an very their X -- -- in to within persistent. people they symptoms. system compromised looking and inclusion, be

Operator

There are will I no Jennifer call further Ms. to queue back questions at now time. over in the turn this Viera.

Jennifer Viera

everyone, for us Thank joining you, this afternoon.

evening. Have e-mail any have Thanks again. feel me. to a additional you in If good call give or a us free please office the questions,

Operator

for gentlemen, participating. this call. concludes and Ladies Thank today's conference you

now may You disconnect.

Enanta Pharmaceuticals (ENTA) 5 Aug 202020 Q3 Earnings call transcript